GI INNOVATION, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,780 KRW | -1.69% |
|
-1.16% | +6.06% |
| 2023 | GI Innovation, Inc.(KOSDAQ:A358570) added to S&P Global BMI Index | CI |
| 2023 | GI Innovation, Inc. has completed an IPO in the amount of KRW 26 billion. | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2023 * | 13B 9.5M 793M | Sales 2024 * | 198B 145M 12.08B | Capitalization | 564B 412M 34.43B |
|---|---|---|---|---|---|
| Net income 2023 * | -72B -52.63M -4.39B | Net income 2024 * | 107B 78.22M 6.53B | EV / Sales 2023 * | 43.4 x |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 2.85 x |
| P/E ratio 2023 * |
-7.76
x | P/E ratio 2024 * |
5.25
x | Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 88.78% |
More Fundamentals
* Assessed data
| 1 day | -1.69% | ||
| 1 week | -1.16% | ||
| Current month | -2.74% | ||
| 1 month | -0.54% | ||
| 3 months | +19.66% | ||
| 6 months | +33.75% | ||
| Current year | +6.06% |
1 week
12 660.00
13 810.00
1 month
12 000.0014 250.00
Current year
9 810.0014 650.00
1 year
8 080.0015 700.00
3 years
8 080.0015 700.00
5 years
8 080.0015 700.00
10 years
8 080.0015 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jun-Ho Hong
CEO | Chief Executive Officer | 52 | - |
Byeong-Geon Lee
CEO | Chief Executive Officer | 67 | 04/22/04 |
Jin-Man Kim
DFI | Director of Finance/CFO | 42 | 01/17/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Byeong-Geon Lee
CEO | Chief Executive Officer | 67 | 04/22/04 |
Su-Yeon Nam
PSD | President | 58 | 01/18/01 |
Geun-Yong An
BRD | Director/Board Member | 49 | 01/22/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/24/10 | 12,780 | -1.69% | 394,930 |
| 09/24/09 | 13,000 | -2.62% | 330,437 |
| 08/24/08 | 13,350 | +0.75% | 766,232 |
| 07/24/07 | 13,250 | -1.05% | 491,220 |
| 03/24/03 | 13,390 | +3.56% | 873,208 |
End-of-day quote Korea S.E., May 10, 2024
More quotes
GI Innovation Inc is a Korea-based company engaged in the research and development of next-generation immunotherapies based on fusion proteins. The Company is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
12,780
KRW
Average target price
21,500
KRW
Spread / Average Target
+68.23%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +6.06% | 420M | |
| +17.96% | 47.02B | |
| +48.77% | 41.86B | |
| +1.17% | 41.76B | |
| -4.27% | 28.8B | |
| +11.42% | 26.05B | |
| -21.39% | 19.15B | |
| +4.86% | 12.55B | |
| +27.29% | 12.34B | |
| -3.50% | 11.82B |
- Stock Market
- Equities
- A358570 Stock